JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

Search

Eli Lilly and Co.

Отворен

СекторЗдравеопазване

767.09 0.38

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

759.04

Максимум

772.32

Ключови измерители

By Trading Economics

Приходи

-6.1B

2.8B

Продажби

-804M

13B

P/E

Средно за сектора

60.989

51.198

EPS

3.34

Дивидентна доходност

0.8

Марж на печалбата

21.678

Служители

47,000

EBITDA

-2B

4.2B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+30.26% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.80%

2.40%

Следващи печалби

6.08.2025 г.

Следваща дата на дивидент

10.06.2025 г.

Следваща дата на екс-дивидент

14.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-157B

671B

Предишно отваряне

766.71

Предишно затваряне

767.09

Настроения в новините

By Acuity

36%

64%

119 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Eli Lilly and Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.05.2025 г., 14:41 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

1.05.2025 г., 11:24 ч. UTC

Печалби

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

29.05.2025 г., 01:00 ч. UTC

Топ новини

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28.05.2025 г., 18:09 ч. UTC

Печалби

Heart Disease Could Be a Goner When These New -2-

28.05.2025 г., 18:09 ч. UTC

Печалби

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27.05.2025 г., 14:02 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27.05.2025 г., 14:01 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27.05.2025 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27.05.2025 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20.05.2025 г., 14:08 ч. UTC

Печалби

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12.05.2025 г., 22:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12.05.2025 г., 18:45 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12.05.2025 г., 17:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7.05.2025 г., 17:01 ч. UTC

Топ новини

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7.05.2025 г., 13:56 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7.05.2025 г., 11:18 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7.05.2025 г., 09:30 ч. UTC

Топ новини

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6.05.2025 г., 20:30 ч. UTC

Топ новини

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4.05.2025 г., 04:05 ч. UTC

Придобивния, сливания и поглъщания

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1.05.2025 г., 21:07 ч. UTC

Пазарно говорене

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1.05.2025 г., 14:07 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1.05.2025 г., 12:47 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1.05.2025 г., 12:00 ч. UTC

Топ новини

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1.05.2025 г., 11:58 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1.05.2025 г., 11:06 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1.05.2025 г., 10:48 ч. UTC

Печалби

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1.05.2025 г., 10:48 ч. UTC

Печалби

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1.05.2025 г., 10:45 ч. UTC

Печалби

Eli Lilly 1Q Adj EPS $3.34 >LLY

1.05.2025 г., 10:45 ч. UTC

Печалби

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1.05.2025 г., 10:45 ч. UTC

Печалби

Eli Lilly 1Q Net $2.76B >LLY

Сравнение с други в отрасъла

Ценова промяна

Eli Lilly and Co. Прогноза

Ценова цел

By TipRanks

30.26% нагоре

12-месечна прогноза

Среден 997.6 USD  30.26%

Висок 1,190 USD

Нисък 700 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Eli Lilly and Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

17

Купи

2

Задържане

1

Продай

Техническа оценка

By Trading Central

N/A / 884.54Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Strong Bearish Evidence

Настроение

By Acuity

119 / 380 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.